Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

Trial Profile

Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Canagliflozin (Primary) ; Dapagliflozin (Primary) ; Liraglutide (Primary) ; Sitagliptin (Primary)
  • Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ALT
  • Most Recent Events

    • 01 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top